CT1812
Mild-to-Moderate Alzheimer's Disease
Key Facts
About Cognition Therapeutics
Cognition Therapeutics is a neuroscience-focused biotech developing small molecule modulators of the sigma-2 receptor complex to halt synaptic damage in neurodegenerative diseases. Its lead asset, CT1812, has generated encouraging biomarker and cognitive signal in multiple Phase 2 studies in Alzheimer's disease and is also being evaluated in dementia with Lewy bodies. The company's strategy leverages a differentiated mechanism of action, supported by non-dilutive grant funding, to advance its pipeline toward pivotal trials in substantial markets with high unmet need. As a micro-cap public company, its near-term value inflection is tied to the clinical readouts from its ongoing SHINE and SHIMMER trials.
View full company profileAbout Cognition Therapeutics
Cognition Therapeutics is a neuroscience-focused biotech developing small molecule modulators of the sigma-2 receptor complex to halt synaptic damage in neurodegenerative diseases. Its lead asset, CT1812, has generated encouraging biomarker and cognitive signal in multiple Phase 2 studies in Alzheimer's disease and is also being evaluated in dementia with Lewy bodies. The company's strategy leverages a differentiated mechanism of action, supported by non-dilutive grant funding, to advance its pipeline toward pivotal trials in substantial markets with high unmet need. As a micro-cap public company, its near-term value inflection is tied to the clinical readouts from its ongoing SHINE and SHIMMER trials.
View full company profileAbout Cognition Therapeutics
Cognition Therapeutics is a neuroscience-focused biotech developing small molecule modulators of the sigma-2 receptor complex to halt synaptic damage in neurodegenerative diseases. Its lead asset, CT1812, has generated encouraging biomarker and cognitive signal in multiple Phase 2 studies in Alzheimer's disease and is also being evaluated in dementia with Lewy bodies. The company's strategy leverages a differentiated mechanism of action, supported by non-dilutive grant funding, to advance its pipeline toward pivotal trials in substantial markets with high unmet need. As a micro-cap public company, its near-term value inflection is tied to the clinical readouts from its ongoing SHINE and SHIMMER trials.
View full company profileAbout Cognition Therapeutics
Cognition Therapeutics is a neuroscience-focused biotech developing small molecule modulators of the sigma-2 receptor complex to halt synaptic damage in neurodegenerative diseases. Its lead asset, CT1812, has generated encouraging biomarker and cognitive signal in multiple Phase 2 studies in Alzheimer's disease and is also being evaluated in dementia with Lewy bodies. The company's strategy leverages a differentiated mechanism of action, supported by non-dilutive grant funding, to advance its pipeline toward pivotal trials in substantial markets with high unmet need. As a micro-cap public company, its near-term value inflection is tied to the clinical readouts from its ongoing SHINE and SHIMMER trials.
View full company profileTherapeutic Areas
Other Mild-to-Moderate Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| ALPHA-1062 | Alpha Cognition | Phase 2 |